Solid Tumor Clinical Trials in West Valley City, Utah

7 studies are recruiting for solid tumor in West Valley City, Utah right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations

   This is a Phase 1/2, open-label, multicenter study evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics and anti-tumor activity of TER-2013 in patients with advanced solid tumors harboring AKT/PI3K/PTEN pathway alterations.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   START Center for Cancer Research, West Valley City, Utah

   Locations

   20 in total

   Run by

   Terremoto Biosciences Inc.

   See if you can join NCT07109726 on ClinicalTrials.gov

2. A Study of PT0253 in Participants With KRAS G12D Mutated Advanced Solid Tumors

   The primary purpose of this study is to evaluate the safety and tolerability, determine the maximally tolerated dose (MTD) and/or recommended Phase 2 dose(s) (RP2D) of PT0253 in adult participants with Kirsten rat sarcoma viral oncogene homolog (KRAS) G12D mutated advanced solid tumors as monothera…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   START Mountain Region, West Valley City, Utah

   Locations

   15 in total

   Run by

   PAQ Therapeutics, Inc.

   See if you can join NCT06797336 on ClinicalTrials.gov

3. A Phase 1 Study of BHV-1530 in Advanced Solid Tumors

   This is a Phase 1, first in human (FIH), Open-Label, Dose Escalation, Dose Expansion and Dose Optimization Study of BHV-1530 as Monotherapy and in Combination with Other Anti-Cancer Agents in Adult Participants with Advanced or Metastatic Solid Tumors

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Site-106, West Valley City, Utah

   Locations

   17 in total

   Run by

   Biohaven Therapeutics Ltd.

   See if you can join NCT06874335 on ClinicalTrials.gov

4. A Study of PT0511 in Participants With KRAS Mutated or Amplified Advanced Solid Tumors

   The primary purpose of this study is to evaluate the safety and tolerability, determine the maximally tolerated dose (MTD) and/or recommended Phase 2 dose(s) (RP2D) of PT0511 in adult participants with solid tumors as monotherapy and in combination with cetuximab in participants with colorectal can…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   START Mountain Region, West Valley City, Utah

   Locations

   9 in total

   Run by

   PAQ Therapeutics, Inc.

   See if you can join NCT07300150 on ClinicalTrials.gov

5. Dose Determining Study of EXS74539 (REC-4539) in Participants With Select Solid Tumors

   The primary purpose of this study is to determine the safety, tolerability, and maximum tolerated dose (MTD) of EXS74539 (REC-4539) in participants with select solid tumors.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   START Mountain Region, West Valley City, Utah

   Locations

   3 in total

   Run by

   Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc.

   See if you can join NCT07517198 on ClinicalTrials.gov

6. Trial to Evaluate the Safety & Tolerability of JBZ-001 in Pts With Advanced Solid and Hematological Malignancies

   This will be a phase 1, open-label, dose-escalation and expansion, FIH trial to evaluate the safety, tolerability, PK, PD, and preliminary efficacy of JBZ-001, a DHODH inhibitor, in patients with refractory solid and hematological malignancies. The study design includes two independent parts: dose …

   Stage

   Phase 1

   Ages

   18 and older

   Site

   START Mountain Region, West Valley City, Utah

   Locations

   2 in total

   Run by

   Jabez Bioscience, Inc

   See if you can join NCT06801002 on ClinicalTrials.gov

7. A Phase 1/2 Study of BHV-1510 (Previously PBI-410) in Advanced Solid Tumors

   This is a Phase 1/2, first in human (FIH), open-label, multicenter study of BHV-1510 monotherapy and in Combination with Cemiplimab in participants with previously treated, advanced solid tumors.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Site-106, West Valley City, Utah

   Locations

   17 in total

   Run by

   Biohaven Therapeutics Ltd.

   See if you can join NCT06384807 on ClinicalTrials.gov